On the other hand, ziltivekimab, a monoclonal antibody directed against IL-6, downstream of IL-1, has shown to reduce inflammatory markers among patients with chronic kidney disease with a rather favourable safety profile.5 The ongoing phase IIIa ARTEMIS trial will determine whether ziltivekimab can effectively reduce the risk of MACE in patients with MI. This evidence concerns the gene IL1B and myocardial infarction.